News Wire

Biogen Inc. says it will not develop natalizumab (Tysabri) for the treatment of acute ischemic stroke after the medication failed a phase 2b trial. Natalizumab, which made nearly $2 billion in 2017 sales, is part of Biogen’s franchise of multiple sclerosis (MS) drugs, a Reuters report noted. Biogen’s…
One hundred years ago, the deadliest influenza pandemic of all time made a ravaging march across the globe. The "Spanish" flu of 1918-19 infected an estimated one-third of the world's population and killed between 50 million and 100 million people, modern epidemiologists estimate. That raises the inevitable…
More children than previously thought may suffer from the health effects that can result when women drink alcohol while pregnant, according to researchers at the University of California San Diego School of Medicine. Their study, published online in the Journal of the American Medical Association, found…
A scientific analysis found stronger evidence that compounds in kratom have opioid properties, according to FDA Commissioner Scott Gottlieb, MD, who added that the agency has now received 44 reports of deaths linked to the Asian plant. In November 2017, the FDA warned the public not to use kratom (Mitragyna…
In a late-stage study, a combination of experimental drugs—encorafenib and binimetinib (Array BioPharma, Inc.)—kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as rival medicine vemurafenib (Zelboraf, Roche), according to…
Positive results have been announced from ACHIEVE I (UBR-MD-01), the first of two pivotal phase 3 clinical trials evaluating the efficacy, safety, and tolerability of Allergan’s orally administered ubrogepant 50 mg and ubrogepant 100 mg compared with placebo in a single migraine attack in adults.…
The FDA has cleared the Embrace smart watch (Empatica, Inc.) for use by patients with epilepsy. Embrace uses advanced machine learning to monitor for the most dangerous kinds of seizures, known as “grand mal” or “generalized tonic-clonic” seizures, and sends an alert to summon caregivers’…
Positive results have been reported from a crucial immunotherapy trial that used a combination of two Bristol-Myers Squibb (BMS) drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), to treat patients with a specific type of non–small-cell lung cancer patients. But previously undisclosed changes BMS…
Positive results have been announced from the phase 3 PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer (CRPC). The results show that the use of enzalutamide (Xtandi, Astellas Pharma/Pfizer) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing…
In theory, ACOs are groups of providers that band together to lower the cost of health while maintaining its quality by using various tools in the value-based care (aka population health) toolkit: care coordination, data analytics, avoidance of low-value services. But a study published in this month’s…
Hospitalizations blamed on the flu may be on track for a record in this increasingly challenging flu season, federal officials said Friday, and 16 more pediatric deaths were reported during the week.  “This is a very difficult season. The hospitalization rate is the highest we’ve seen,” said…
Updated results from a global clinical trial of the CAR T-cell therapy tisagenlecleucel (Kymriah, Novartis) show that children and young adults continued to show high rates of durable, complete remission of their high-risk form of acute lymphoblastic leukemia (ALL), according to a study published in…
Scientists in Japan and Australia have developed a blood test that can identify people who have high levels of a protein associated with Alzheimer's disease. If confirmed by further research, this long-sought test could help in the increasingly desperate search for therapies that halt the progression…
Once-weekly semaglutide (Ozempic, Novo Nordisk) led to greater reductions in HbA1c and body weight compared to dulaglutide (Trulicity, Eli Lilly) in the SUSTAIN 7 trial, according to results published in The Lancet Diabetes & Endocrinology. SUSTAIN 7 investigated the efficacy and safety of 0.5 mg semaglutide…
In an update on pharmaceutical pipeline projects tucked inside its financial results, FierceBiotech reports, Swiss drugmaker Roche announced that it was pulling the plug on several early- and late-stage candidates. The casualties: Lampalizumab (RG7417), a phase 3 drug that last fall failed two tests:…

Pages